Glaxo Response To Alli Tampering Leads 2014 Business-Finance Articles
This article was originally published in The Tan Sheet
Executive Summary
Alli recall mitigates reputation damage, Sanofi loads up with Cialis OTC license and P&G’s reduction could be competitors’ gain.
You may also be interested in...
Sanofi Board Forces Out CEO Chris Viehbacher Amid Lantus Woes
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
Lonely At The Top? Not In OTC Sector As Bayer, GSK/Novartis Challenge J&J
Bayer closes its acquisition of Merck & Co.’s consumer business, aiming to become the top OTC player and saying other consumer product acquisitions could follow. Glaxo and Novartis look to close their agreement to combine their OTC businesses in the first half of 2015.
With OTC Cialis Rights, Sanofi Launches Latest Salvo In Consumer Sector Battle
Sanofi gains rights from Eli Lilly & Co. to apply for OTC approval of Cialis in the U.S., Europe, Canada and Australia. Launching the first OTC product indicated for erectile dysfunction would mark another milestone in Sanofi CEO Chris Viebacher’s mission to move the firm into the neighborhood of global OTC leaders.